DUBLIN – Ipsen SA is putting down $25 per share, or $1.04 billion in cash, to acquire Clementia Pharmaceuticals Inc. and is on the hook for a contingent value right (CVR) worth another $6 per share, or $263 million, which is tied to FDA acceptance of Clementia's NDA for its lead drug, palovarotene, in multiple osteochondromas (MO).